Nossel H L, Ti M, Kaplan K L, Spanondis K, Soland T, Butler V P
J Clin Invest. 1976 Nov;58(5):1136-44. doi: 10.1172/JCI108566.
Plasma fibrinopeptide A (FPA) concentrations were measured in clinical blood samples incubated in the collecting syringe for different time periods before addition to heparin and Trasylol, and the rate of in vitro generation of FPA was calculated as the mean increment in FPA concentration per minute over the linear portion of the generation curve. 36 normal individuals had a mean plasma FPA level of 0.64 +/- 0.56 pmol/ml and an FPA generation rate of less than 0.5 pmol/ml per min. Clinical samples with elevated plasma FPA levels manifested slow (less than 1 pmol/ml per min) (28 patients) or rapid FPA generation (greater than 1 pmol/ml per min) (33 patients). Slow FPA generation was found in 10/10 patients with venous thrombosis, in 4/4 with aortic aneurysm, and in several patients with acquired hypofibrinogenemia. In one such patient, addition of fibrinogen resulted in rapid FPA generation whereas thrombin addition was without effect. Rapid FPA generation was generally linear, was usually associated with slower fibrinopeptide B generation and was inhibited by parenteral or in vitro heparin. It is thought to reflect increased thrombin activity and was seen in patients with pulmonary embolism, active systemic lupus erythematosus, renal transplant rejection, and after infusion of prothrombin concentrates. The initial rate of FPA cleavage by thrombin at fibrinogen concentrations from 0.05 to 4 mg/ml showed little change between 2 and 4 mg/ml with a Km of 2.99 muM. At a fibrinogen concentration of 2.5 mg/ml the FPA cleavage rate was 49.2 +/- 1.6 nmol/ml per min per U of thrombin. Exogenous thrombin added to normal blood generated 21.7 nmol/ml per U of thrombin FPA in the first minute with a nonlinear pattern reflecting inactivation of thrombin and the presence of alternative substrates. Hence, the thrombin concentration in the blood cannot be calculated from the FPA generation rate. The FPA generation rates in clinical samples with rapid generation (1-28 pmol/ml per min) could be produced by 2 X 10(-5) to 5.6 X 10(-4) thrombin U/ml acting on purified fibrinogen at physiological conditions of pH, ionic strength, and temperature.
在添加肝素和抑肽酶之前,将临床血样在采血注射器中孵育不同时间段,然后测定血浆纤维蛋白肽A(FPA)浓度,并将FPA的体外生成速率计算为生成曲线线性部分每分钟FPA浓度的平均增加值。36名正常个体的血浆FPA平均水平为0.64±0.56 pmol/ml,FPA生成速率低于0.5 pmol/ml每分钟。血浆FPA水平升高的临床样本表现出缓慢(低于1 pmol/ml每分钟)(28例患者)或快速FPA生成(高于1 pmol/ml每分钟)(33例患者)。在10/10例静脉血栓形成患者、4/4例主动脉瘤患者以及数例获得性纤维蛋白原血症患者中发现FPA生成缓慢。在其中1例患者中,添加纤维蛋白原导致FPA快速生成,而添加凝血酶则无效果。快速FPA生成通常呈线性,通常与较慢的纤维蛋白肽B生成相关,并受到胃肠外或体外肝素的抑制。它被认为反映了凝血酶活性增加,见于肺栓塞、活动性系统性红斑狼疮、肾移植排斥反应患者以及输注凝血酶原浓缩物后。在纤维蛋白原浓度为0.05至4 mg/ml时,凝血酶对FPA的初始裂解速率在2至4 mg/ml之间变化不大,Km为2.99 μM。在纤维蛋白原浓度为2.5 mg/ml时,每单位凝血酶的FPA裂解速率为49.2±1.6 nmol/ml每分钟。添加到正常血液中的外源性凝血酶在第一分钟每单位凝血酶产生21.7 nmol/ml的FPA,其非线性模式反映了凝血酶的失活以及存在替代底物。因此,无法根据FPA生成速率计算血液中的凝血酶浓度。快速生成(1至28 pmol/ml每分钟)的临床样本中的FPA生成速率可能是由2×10⁻⁵至5.6×10⁻⁴单位/毫升的凝血酶在生理pH、离子强度和温度条件下作用于纯化的纤维蛋白原产生的。